NR3C2 and hydrops fetalis: Several drugs routinely used in HF, such as angiotensin-converting enzyme inhibitors, angiotensin receptor-neprilysin inhibitor, beta-blockers, and mineralocorticoid receptor antagonists, have been associated with greater survival, a reduction in the risk of HF hospitalization, and a reduction in symptoms in patients with HF with reduced ejection fraction (30).